Q-omics provides the consensus-scored ZSCAN26 profile across patient tissues and cancer cell-line models. ZSCAN26 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZSCAN26 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ZSCAN26 RNA expression shows 20,662 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, THCA, and THYM as cancer lineages where ZSCAN26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN26 survival associations across molecular data types. ZSCAN26 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN26 RNA expression–survival associations across cancer types. High ZSCAN26 expression shows unfavorable associations in LIHC, LUSC and KICH, but favorable associations in LUAD, GBM and THYM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZSCAN26 RNA expression.
This table summarizes ZSCAN26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZSCAN26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN26 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in LIHC, KIRC and HNSC. The THCA box plot shows higher ZSCAN26 RNA expression in normal versus tumor tissue (log2 FC = −0.594, t-test p < 0.001).
This table shows molecular features associated with ZSCAN26 in patient tissues and cancer cell lines. In patient samples, ZSCAN26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_NSCLC_LUSC.
